Altimmune (ALT) Total Non-Current Liabilities (2010 - 2026)

Altimmune (ALT) has reported Total Non-Current Liabilities for 17 consecutive years, with $45.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 764.19% year-over-year to $45.8 million; the TTM figure through Mar 2026 stood at $45.8 million (up 764.19% YoY), while the FY2025 annual figure was $49.3 million, up 824.65% from the prior year.
• Total Non-Current Liabilities retreated to $45.8 million in Q1 2026 per ALT's latest filing, from $49.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $49.3 million in Q4 2025 and bottomed at $4.1 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $16.7 million across 5 years, with a median of $5.8 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 66.41% — and 2025, when it jumped 824.65%.
• Altimmune's Total Non-Current Liabilities stood at $4.6 million in 2022, then declined by 3.99% to $4.4 million in 2023, then climbed by 21.19% to $5.3 million in 2024, then surged by 824.65% to $49.3 million in 2025, then decreased by 7.01% to $45.8 million in 2026.
• Business Quant data shows ALT's Total Non-Current Liabilities at $45.8 million in Q1 2026, $49.3 million in Q4 2025, and $27.1 million in Q3 2025.